<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632333</url>
  </required_header>
  <id_info>
    <org_study_id>TPR07-079</org_study_id>
    <nct_id>NCT00632333</nct_id>
  </id_info>
  <brief_title>Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer</brief_title>
  <official_title>Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teikyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teikyo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immune response of multiple peptides
      (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with
      chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable,
      advanced or recurrent esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up-regulated ling cancer 10 (URLC10), TTK protein kinase (TTK) and K homology domain
      containing protein over expressed in cancer (KOC1) were identified as new targets of tumor
      associated antigens using cDNA microarray technologies combined with the expression profiles
      of normal and cancer tissues. Furthermore, anti-angiogenic therapy is now considered to be
      one of promising approaches for treating cancer. Vascular endothelial growth factor receptor
      1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) are essential targets
      for tumor angiogenesis. Epitope peptides for these targets are able to induce cytotoxic T
      lymphocytes (CTL) restricted to HLA-A *2402 in vivo. On the other hand, chemotherapy (CDDP,
      5-FU) plus radiation therapy has been to be a standard treatment for unresectable advanced
      esophageal cancer. In this clinical trial, we evaluate the safety and immune responses of
      different doses of multiple peptides (URLC10, TTK, KOC1, VEGFR1, and VEGFR 2) emulsified with
      Montanide ISA 51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in
      treating patients with unresectable, advanced or recurrent esophageal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety(toxicities as assessed by NCI CTCAE version3)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peptide specific CTL induction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTH to peptide</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of regulatory T cells</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed by RECIST criteria</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil</intervention_name>
    <description>Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CDDP</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have unresectable, locally advanced, recurrent or metastatic disease of
             esophageal cancer.

          2. measurable disease by CT scan

          3. ECOG performance status of 0 to 2

          4. Expected survival of at lease 3months

          5. Patients must be HLA-A2402

          6. Laboratory values as follow:

               -  WBC &gt; 2000/mm3,

               -  Platelet count &gt; 75000/mm3,

               -  Total bilirubin &lt; 1.5 x the institutional normal upper limits,

               -  Creatinine &lt; 1.5 x the institutional normal upper limits,

               -  AST. ALT. ALP &lt; 2.5 x the institutional normal upper limits

          7. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Pregnancy (women of childbearing potential:Refusal or inability to use effective means
             of contraception)

          2. Breastfeeding

          3. Active or uncontrolled infection

          4. Prior chemotherapy,radiation therapy or immunotherapy within 4 weeks

          5. Concurrent treatment with steroid or immunosuppressing agent

          6. Patient with peptic ulcer disease

          7. Active or uncontrolled other malignancy

          8. Other malignancy within 5 years prior to entry into the study, expect for treated
             non-melanoma skin cancer and cervical carcinoma in situ

          9. Disease to the central nervous system

         10. Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kota Okinaga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Teikyo University , Department Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hisae Iinuma, PhD</last_name>
    <phone>+81-33-964-1211</phone>
    <email>iinuma@med.teikyo-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>2-11-1 Kaga Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisae Iinuma, PhD</last_name>
      <phone>+81-33-964-1211</phone>
      <email>iinuma@med.teikyo-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hisae Iinuma, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Yildirim Z, Kotuk M, Iraz M, Kuku I, Ulu R, Armutcu F, Ozen S. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine. Pulm Pharmacol Ther. 2005;18(5):367-73. Epub 2005 Mar 23.</citation>
    <PMID>15939316</PMID>
  </reference>
  <reference>
    <citation>Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002 Jun 17;195(12):1575-84. Erratum in: J Exp Med 2002 Aug 19;196(4):557.</citation>
    <PMID>12070285</PMID>
  </reference>
  <reference>
    <citation>Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. Epub 2002 Nov 4.</citation>
    <PMID>12415261</PMID>
  </reference>
  <reference>
    <citation>Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens. 1996 Feb;47(2):93-101.</citation>
    <PMID>8851721</PMID>
  </reference>
  <reference>
    <citation>Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005 Jul 15;175(2):820-8. Erratum in: J Immunol. 2005 Nov 1;175(9):6235. Prete, Salvatore [corrected to Prete, Salvatore Pasquale].</citation>
    <PMID>16002679</PMID>
  </reference>
  <reference>
    <citation>Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol. 2002 Sep;33(9):863-70.</citation>
    <PMID>12378509</PMID>
  </reference>
  <reference>
    <citation>Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May;97(5):411-9.</citation>
    <PMID>16630140</PMID>
  </reference>
  <reference>
    <citation>Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T, Hasegawa S, Satoh S, Ohgi S, Tahara H, Furukawa Y, Nakamura Y. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005 Aug;96(8):498-506.</citation>
    <PMID>16108831</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998 Mar;4(3):321-7.</citation>
    <PMID>9500606</PMID>
  </reference>
  <reference>
    <citation>Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004 Oct;34(10):615-9. Erratum in: Jpn J Clin Oncol. 2005 Feb;35(2):108.</citation>
    <PMID>15591460</PMID>
  </reference>
  <reference>
    <citation>Waters JS, Tait D, Cunningham D, Padhani AR, Hill ME, Falk S, Lofts F, Norman A, Oates J, Hill A. A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Ann Oncol. 2002 Nov;13(11):1763-70.</citation>
    <PMID>12419749</PMID>
  </reference>
  <reference>
    <citation>Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999 Jan 18;80(2):219-30.</citation>
    <PMID>9935203</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of Surgery</name_title>
    <organization>Teikyo University</organization>
  </responsible_party>
  <keyword>Epitope peptide</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

